FDA
-
-
-
-
-
-
-
FDA accepts Genentech's application for Lunsumio and Polivy combo
-
-
-
-
-
-
-
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
-
-
-
-
-
-
-
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
-
-
-
-
-
-
-
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
-
-
-
-
-
-
-
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
-
-
-
-
-
-
-
Flatiron Health Announces 12 Abstracts Accepted to Be Presented at ISPOR Europe 2025
-
-
-
-
-
-
-
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
-
326,211 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

